Industry watchers responded mostly positively to the commissioner’s new voucher program, but worries remain over staffing cuts at the agency.

Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetesTHE WOODLANDS, Texas, June ...

Detailed price information for Xeris Pharmaceuticals Inc (XERS-Q) from The Globe and Mail including charting and trades.

xAI lexicon: A guide to tech terms related to Elon Musk's supercomputer in Memphis From Georgia to Virginia, how have areas navigated data center growth and energy demands? MLGW's Doug McGowen ...

Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The firm has a market cap of $140.48 million, a price-to-earnings ratio of -0.76 and a beta of 1.04.

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for ...

Equities research analysts at StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) in a report issued on Wednesday. The firm set a “sell ...

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript March 6, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11.

THE WOODLANDS, Texas - Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX), a biopharmaceutical company, announced today a significant restructuring plan that includes the elimination of its commercial ...